

Sample ID: **ACTN01029999T** | Gender: **Male** | Birth year: **1950** | WHO: **1**Tumor: **Skin - Melanoma** | Lesions: **Abdominal, CNS, Liver, Lung** | Stage: **IV**

Summary

Patient clinical history (12-Mar-2022)

Relevant systemic treatment history	Vemurafenib (3/2021), Ipilimumab (2022)
Other oncological history	Resection (2020)
	Previous primary tumor: Bone/Soft tissue Schwannoma (3/2019, considered active)
Relevant non-oncological history	Pancreatitis, Myocardial infarction

Molecular results

Previous relevant molecular results	ERBB2 3 + (IHC)
-------------------------------------	------------------------

WGS molecular results (17-Mar-2022)

Biopsy location	Liver
Events with approved treatment evidence in general	BRAF V600E, High TML
Events with trial eligibility in local database	BRAF V600E, High TML
Additional events with trial eligibility in NL (external)	None
Additional events with experimental evidence (general)	None
Additional events with other responsive evidence in general	None
Events with resistance evidence in general	BRAF V600E: Erlotinib

Approved treatments considered eligible

Treatment
Not yet determined

local trials that are open and considered eligible (1)

Trial	Acronym	Cohort	Molecular	Warnings
Test Trial 1	TEST-TRIAL-1	Cohort B	No	None

external trials potentially eligible based on molecular results

Event	Trials
BRAF V600E	Trial 1
High TML	Trial 1

Clinical Details

Patient current details (12-Mar-2022)

Unresolved toxicities grade => 2	Fatigue (2), Dizziness
Significant aberration on latest ECG	Atrial arrhythmia
Cancer-related complications	Ascites
Known allergies	Wasps (Environment), Pembrolizumab (Medication)
Recent surgeries	20-Feb-2022

Tumor details (12-Mar-2022)

Measurable disease	Yes
CNS lesion status	CNS (active)
Brain lesion status	No known brain lesions

Laboratory results (12-Mar-2022)

Liver function	Total bilirubin		
	ASAT	(< 33 U/L)	36 U/L (no trend information available)
	ALAT		
	ALP		
	Albumin		
Kidney function	Creatinine		
	CKD-EPI eGFR	(> 100 mL/min)	> 100 mL/min (20-Feb-2022)
Other	Hemoglobin	(6.5 - 9.5 mmol/L)	5.5 mmol/L (no trend information available)
	Thrombocytes	(155 - 350 10 ⁹ /L)	150 10 ⁹ /L (out of range for 2 cons. measurements, trend down)
	LDH	(< 245 U/L)	240 U/L (02-Mar-2022)

Medication details

Medication	Categories	Start date	Stop date	Active?	Dosage	Frequency
Ibuprofen	NSAIDs	20-Feb-2022	06-Apr-2022	Yes	750 - 1000 mg	1 / day

Blood transfusions

Product	Date
Thrombocyte concentrate	07-Mar-2022

Trial Matching Summary

local trials that are closed but considered eligible (0)

Trial	Acronym	Cohort	Molecular	Warnings
None				

local trials not considered eligible (3)

Trial	Acronym	Cohort	Open	Ineligibility reasons
Test Trial 1	TEST-TRIAL-1	Cohort A	Yes	fail general
Test Trial 1	TEST-TRIAL-1	Cohort C	Yes	Cohort blacklisted
Test Trial 2	TEST-TRIAL-2		Yes	fail general

Trial Matching Details

Potentially eligible trials & cohorts

Test Trial 1

Potentially eligible	Yes
Acronym	TEST-TRIAL-1
Title	This is the first ACTIN test trial

Rule	Reference	Evaluation
I-01	Is adult	PASS pass specific
E-01	This rule has 2 conditions: 1. Patient has no active brain metastases. 2. Patient has exhausted SOC.	NOT_EVALUATED not evaluated specific

Test Trial 1 - Cohort A

Cohort ID	A
Potentially eligible	No
Open for inclusion?	Yes

Rule	Reference	Evaluation
I-02	Has no active CNS metastases	FAIL fail specific

Test Trial 1 - Cohort B

Cohort ID	B
Potentially eligible	Yes
Open for inclusion?	Yes

Test Trial 1 - Cohort C

Cohort ID	C
Potentially eligible	No
Open for inclusion?	Yes
Blacklisted for eligibility?	Yes

Other trials & cohorts

Test Trial 2

Potentially eligible	No	
Acronym	TEST-TRIAL-2	
Title	This is the second ACTIN test trial	
Rule	Reference	Evaluation
I-01	Should have active infection	FAIL
		fail specific